Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Structure Therapeutics Inc. (the "Company") held its 2026 Annual General Meeting of Shareholders (the "Annual General Meeting"). As of April 20, 2026, the record date for the Annual General Meeting, 213,213,565 ordinary shares were outstanding and entitled to vote at the Annual General Meeting. A summary of the matters voted upon by shareholders at the Annual General Meeting is set forth below.

Proposal 1: Election of Directors

Ted W. Love M.D., Raymond Stevens, Ph.D. and Daniel G. Welch were elected as a Class III directors, to hold office until the 2029 Annual General Meeting of Shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm

The Company's shareholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

Proposal 3: Advisory vote on the compensation of the Company's named executive officers

On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual General Meeting. The voting results are as follows: